- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Research ADCs
- Research Apoptosis
- Research B cell
- Research BRAF
- Research HDIs
- Research HER Pathways
- Research MET
- Research VEGF
- Why is the VEGF ligand essential throughout tumor development?
- What are the strategies for inhibiting the VEGF pathway?
- What are the effects of direct VEGF ligand inhibition?
- Why is continued VEGF inhibition important?
- Why do tumors progress?
- The role of VEGF across tumor types
- Slide decks and videos
- Glossary
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Clinical Trials
- Future Directions
- Antibody-Drug conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- How are ADCs designed to work?
- VEGF and prognosis in multiple myeloma
- Glossary
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Monoclonal antibody
- Multimedia Resources
- Receptor-Mediated Endocytosis
- Research ADCs
- Serum VEGF as a clinical marker
- Stable linker
- Targeting cancers with ADCs
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- What are ADCs?
- Glycoengineered Antibodies
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Non-Antibody Biologics
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Targeted Small Molecules
- Apoptosis
- VEGF expression in gastric cancer
- Gastric Cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- Glossary
- VEGF expression and liver metastases
- MAPK Signaling
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- PI3K/Akt/mTOR Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Traditional Monoclonal Antibodies
- B-cell Surface Proteins
- Glossary
- VEGF expression in gastric cancer
- Gastric Cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Angiogenic Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Antibody-Drug conjugates
VEGF and Gastric Cancer Correlation
VEGF is a potent proangiogenic factor released by many solid tumors, and the large majority of gastric carcinomas have elevated levels of VEGF.1-3 As a clinical marker, sVEGF levels have been found to be significantly higher in gastric cancer patients than in controls (P<0.0001). sVEGF levels are significantly correlated with disease stage, (P=0.01) and with distant metastases (P=0.004).4
High VEGF expression is characteristic of gastric carcinomas,5 where VEGF and other growth factors form an autocrine loop.6 A significant relationship exists between VEGF expression and MVD in gastric cancers (P=0.008), where MVD was found to be elevated by 46% in VEGF-positive tumors.7 High MVD has been associated with an increased risk of metastases. Tumors positive for VEGF are associated with increased risk of hepatic metastases.8,9
Prognostically, VEGF expression is associated with shorter overall survival time, as well as diminished disease-free survival.3 Positive correlations exist between MVD and VEGF expression.3 MVD has been found to be an independent risk factor for survival in gastric carcinoma, where significant differences in overall survival have been found between patients with low and high MVD (P<0.001).7
References:
- 1.
- Suzuki S, Dobashi Y, Hatakeyama Y, et al. BMC Cancer. 2010;10:659. PMID: 21118571
- 2.
- Nagy JA, Feng D, Vasile E, et al. Lab Invest. 2006;86:767-780. PMID: 16732297
- 3.
- Fondevila C, Metges JP, Fuster J, et al. Br J Cancer. 2004;90:206-215. PMID: 14710231
- 4.
- Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Ann Surg. 2002;236:37-42. PMID: 12131083
- 5.
- Kösem M, Tuncer I, Kotan Ç, et al. Hepatogastroenterology. 2009;56:1236-1240. PMID: 19760978
- 6.
- Smith MG, Hold GL, Tahara E, et al. World J Gastroenterol. 2006;12:2979-2990. PMID: 16718776
- 7.
- Zhao HC, Qin R, Chen XX, et al. World J Gastroenterol. 2006;12:7598-7603. PMID: 17171787
- 8.
- Maeda K, Chung YS, Ogawa Y, et al. Cancer. 1996;77:858-863. PMID: 8608475
- 9.
- Tanigawa N, Amaya H, Matsumura M, et al. Cancer Res. 1996;56:2671-2676. PMID: 8653715